Objective To investigate the application effect of transcatheter arterial chemoembolization (TACE) combined with FOLFOX regimen continuous hepatic arterial infusion chemotherapy in patients with Barcelona stage B(BCLC-B) primary liver cancer (PHC). Methods Seventy patients with PHC stage BCLC-B admitted to Chaozhou Central Hospital from May 2018 to May 2021 were selected as the study subjects, and they were divided into experimental group (n=35) and control group (n=35) by random number table method. The experimental group was treated with continuous hepatic arterial infusion chemotherapy with TACE+FOLFOX regimen, and the control group was treated with TACE. The disease control rate, objective response rate, incidence of adverse reactions, and tumor marker levels before and after treatment were compared between the two groups. Results The objective response rate and disease control rate of the experimental group were higher than those of the control group, and the differences were statistically significant (P<0.05). After treatment, the levels of alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA) and carbohydrate antigen (CA199) in the experimental group were lower than those in the control group, and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion Continuous hepatic arterial infusion chemotherapy with TACE combined with FOLFOX regimen has a good short-term effect on patients with BCLC-B PHC. The disease control effect of patients is significantly improved, and the level of serum tumor markers is reduced. The safety is tolerable, and it is worthy of further study.